- Sonoran Desert Chorale Bids Farewell to Founder and Music DirectorPosted 19 hours ago
- Six Salt River Project Employees Honored for VolunteerismPosted 2 days ago
- Visit Mesa Becomes First-Ever Autism-Certified Destination Marketing OrganizationPosted 6 days ago
- Flinn Foundation Selects 20 Excelling Arizona High-School Seniors as 2019 Flinn ScholarsPosted 1 week ago
- Award-Winning Journalist Lisa Ling to Keynote United Way LuncheonPosted 1 week ago
- Gateway for Cancer Research Approves $1.5 Million Grant to Fund Pediatric Brain Cancer Research at PCHPosted 2 weeks ago
Gateway for Cancer Research Approves $1.5 Million Grant to Fund Pediatric Brain Cancer Research at PCH
Gateway for Cancer Research, a nonprofit dedicated to funding transformational cancer research, has approved a $1.5 million grant to help physician scientists at Phoenix Children’s Hospital make progress in combating one of the most devastating, aggressive pediatric brain tumors, called Diffuse Intrinsic Pontine Glioma (DIPG).
Led by renowned pediatric oncologist Cynthia Wetmore, MD, PhD, the Division Chief of Hematology/Oncology and Director of the Center for Cancer and Blood Disorders at Phoenix Children’s, the study, called CUPID, will test a therapy combining a customized peptide vaccine with a checkpoint inhibitor to combat the incurable pediatric brain stem cancer, DIPG. This is a collaboration with Stephen Johnston, PhD at Arizona State University, who has developed the technology for identifying peptides for the vaccine. If ultimately successful, the research could be the first therapeutic progress for DIPG in over 30 years.
Brain tumors are the most common solid tumor in children – accounting for approximately 25 percent of all childhood cancers. DIPGs represent approximately 75 percent of all pediatric brainstem tumors and generally do not appear in adults. Due to their location, DIPGs cannot be removed surgically. The only effective treatment is palliative radiation therapy.
“Leading research of this magnitude helps Phoenix Children’s Center for Cancer and Blood Disorders achieve its national standing as a top 20 pediatric cancer program in the U.S.,” said Robert L. Meyer, President and CEO of Phoenix Children’s. “This shows our physicians seek out and implement new solutions for pediatric populations suffering from aggressive illness. We want to change these trends.
“In a time where we see such frequent, innovative advancements in science and medicine, it is disappointing there haven’t been any major therapeutic advancements made for DIPG in over three decades. Phoenix Children’s is determined to turn the page on DIPG treatment and work towards a cure. We’re honored to receive Gateway’s first-ever Arizona grant award, and we are excited to get to work.”